Skip to content

US · CRVS · BIOTECHNOLOGY

Corvus Pharmaceuticals, Inc. (CRVS) intrinsic value and stock valuation

$9.67as of 2026-11-21 · Mkt cap 1.17B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Corvus Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values CRVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CRVS’s statements →

Corvus Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 corvuspharma.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-15.28M
20142025
Free cash flow
-$-32.97M
20142025
Total equity
$61.2M-3.2% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-42.97M-$-27.55M-$-23.41M-$-32.56M-$-38.63M
Net income-$-15.28M-$-62.29M-$-27.03M-$-41.31M-$-43.24M
EPSd-$-191.62K-$-1.02M-$-562.77K-$-887.43K-$-1.03M
Operating cash flow-$-32.8M-$-25.42M-$-23.93M-$-27.02M-$-36.72M
Capital expenditure-$-170K$0.00-$-30K-$-270K-$-10K
Free cash flow-$-32.97M-$-25.42M-$-23.97M-$-27.29M-$-36.72M
Total assets$71.1M$68.9M$45.6M$68.2M$109.5M
Total debt$940K$1.12M$1.37M$2.6M$3.65M
Net debt-$-3.64M-$-7.62M-$-11.25M-$-10.56M-$-59.81M
Total equity$61.2M$32.6M$38.7M$56.1M$97.2M
Cash and short-term investments$56.8M$52M$27.2M$42.3M$69.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$100K$0.00$0.00$0.00$0.00
Gross profit-$-100K$0.00$0.00$0.00$0.00
Research and development expenses$33.7M$19.4M$16.5M$24.5M$29.1M
Selling, general and administrative expenses$9.25M$8.16M$6.88M$8.1M$9.52M
Other expenses-$-100K$0.00$0.00$0.00$0.00
Operating expenses$42.9M$27.6M$23.4M$32.6M$38.6M
Cost and expenses$43M$27.6M$23.4M$32.6M$38.6M
Interest income$2.5M$1.82M$1.58M$650K$0.00
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$100K$90K$150K$370K$460K
Ebitda-$-15.18M-$-62.21M-$-26.88M-$-40.94M-$-42.77M
Operating income-$-42.97M-$-27.55M-$-23.41M-$-32.56M-$-38.63M
Total other income/expenses, net$27.7M-$-34.74M-$-3.62M-$-8.74M-$-4.61M
Income before tax-$-15.28M-$-62.29M-$-27.03M-$-41.31M-$-43.24M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-15.28M-$-62.29M-$-27.03M-$-41.31M-$-43.24M
Weighted average shares outstanding$79M$61M$48M$46.6M$41.9M
Weighted average diluted shares outstanding$79.7M$61M$48M$46.6M$41.9M
Balance sheet
20252024202320222021
Cash and short-term investments$56.8M$52M$27.2M$42.3M$69.5M
Net receivables$370K$220K$60K$630K$540K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$58.2M$54.4M$28M$43.7M$71.3M
Property, plant and equipment, net$1.06M$1.33M$1.39M$2.57M$3.64M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$11M$12.5M$16.1M$21.9M$34.3M
Total non-current assets$12.9M$14.5M$17.6M$24.6M$38.1M
Total assets$71.1M$68.9M$45.6M$68.2M$109.5M
Accounts payable$2.49M$2.58M$1.52M$1.98M$1.56M
Short-term debt$400K$180K$1.37M$1.23M$1.05M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.38M$35.4M$6.87M$10.8M$9.69M
Long-term debt$530K$940K$0.00$1.37M$2.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$530K$940K$0.00$1.37M$2.6M
Capital lease obligations$530K$1.12M$1.37M$2.6M$3.65M
Total liabilities$9.91M$36.3M$6.87M$12.1M$12.3M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-412.29M-$-397.01M-$-334.72M-$-307.69M-$-266.38M
Accumulated other comprehensive income (loss)-$-900K-$-1.29M-$-970K-$-560K$1.87M
Total equity$61.2M$32.6M$38.7M$56.1M$97.2M
Total investments$63.2M$55.8M$30.7M$51M$40.3M
Total debt$940K$1.12M$1.37M$2.6M$3.65M
Net debt-$-3.64M-$-7.62M-$-11.25M-$-10.56M-$-59.81M
Cash flow statement
20252024202320222021
Net income-$-15.28M-$-62.29M-$-27.03M-$-41.31M-$-43.24M
Depreciation and amortization$100K$90K$150K$370K$460K
Stock-based compensation$5.33M$3M$2.15M$2.69M$4.23M
Change in working capital$3.58M-$-1.65M-$-3.59M$1.41M-$-3.24M
Accounts receivable$40K-$-50K$560K-$-80K-$-510K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-90K$1.06M-$-450K$410K-$-1.9M
Net cash provided by operating activities-$-32.8M-$-25.42M-$-23.93M-$-27.02M-$-36.72M
Investments in property, plant and equipment-$-170K$0.00-$-30K-$-270K-$-10K
Acquisitions, net$0.00$10K$0.00$20K-$-20K
Net cash used for investing activities-$-7.8M-$-27.48M$15.5M-$-23.28M$21.6M
Common stock issued$36.4M$16.4M$7.84M$0.00$60.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$36.4M$49M$7.86M$0.00$62.2M
Net change in cash-$-4.16M-$-3.88M-$-540K-$-50.3M$47M
Cash at end of period$4.58M$8.74M$12.6M$13.2M$63.5M
Operating cash flow-$-32.8M-$-25.42M-$-23.93M-$-27.02M-$-36.72M
Capital expenditure-$-170K$0.00-$-30K-$-270K-$-10K
Free cash flow-$-32.97M-$-25.42M-$-23.97M-$-27.29M-$-36.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Corvus Pharmaceuticals, Inc.

        Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

        CEO
        Richard A. Miller
        Employees
        37
        Beta
        0.82

        Explore

        Frequently asked questions

        What is the intrinsic value of Corvus Pharmaceuticals, Inc. (CRVS)?

        InvestorsCraft does not currently publish an intrinsic value for CRVS. How the IC value is calculated.

        Is CRVS undervalued?

        InvestorsCraft does not publish an undervaluation signal for CRVS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.